An Early Phase 1 interventional study of SHE-OUD in Sexual Violence, Opioid Use Disorder and Posttraumatic Stress Disorder, sponsored by Lifespan. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Lifespan · Early Phase 1, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if the SHE-OUD program helps women who are receiving buprenorphine treatment for opioid use disorder (OUD), have experienced sexual violence, and have PTSD. The study will examine whether the program is practical to deliver, safe, and acceptable to participants. The main questions it aims to answer are: Is SHE-OUD feasible, acceptable, and satisfying for women in OUD treatment who have experienced sexual violence and have PTSD? Does SHE-OUD increase participants' engagement in mental health treatment for PTSD? The study will first evaluate SHE-OUD in a small open trial, then compare SHE-OUD to a control condition in a randomized trial to see if SHE-OUD increases engagement in mental health treatment. Participants will: complete the SHE-OUD program (or, in the randomized trial, either SHE-OUD or the control condition), continue regular buprenorphine treatment for OUD, complete assessments at the start of the study and at a 1-month follow-up, and answer questions about mental health, treatment engagement, and satisfaction with the program.
The goal of this R61/R33 is to adapt SHE for use in outpatient OUD treatment (SHE-OUD), and evaluate its feasibility, acceptability, and outcomes among women with SV and PTSD in MOUD treatment. To be included, women must report current OUD, be enrolled in OUD treatment, be treated with buprenorphine, report prior SV, report current PTSD, and not be engaged in mental health treatment for PTSD. As SHE was developed for women veterans, only women are included in this phase of development/testing. Activities in the R61 Phase focus on building, adapting, and testing the feasibility of SHE-OUD. Following the assessment, decision, adaptation, production, topical experts integration, training, testing (ADAPT-ITT) framework, information from informant interviews (N = 10), focus groups (N = 30), stakeholder interviews (N = 6) and a Research Advisory Board will be leveraged to adapt the program. Next, the intervention will be evaluated in an open trial (N = 20) of SHE-OUD among women meeting study eligibility criteria to demonstrate the feasibility (Aim 1a) and safety (Aim 1b) of the research design, feasibility, acceptability, satisfaction and utility of SHE-OUD (i.e., completion rate, acceptance, satisfaction, and utility scores; Aim 2a,2b,2c,2d). Assessments will explore shifts in mental treatment engagement outcomes at a 1-month follow-up (Aim 3). To proceed to the R33, 80% of participants will complete the 1-month follow-up within 2 weeks of the due date (Aim 1a), and no serious study-related adverse events will be reported (Aim 1b). Further, 80% will complete the assigned SHE-OUD modules (Aim 2a), participants must report: an average acceptability score of >3 (out of 5) for each SHE-OUD component (Aim 2b); an average >24 on the Client-Satisfaction Questionnaire-8 (Aim 2c); and an average >90 on the Utility and Impact Questionnaires (Aim 2d). Regarding mental health treatment engagement, assessments will examine whether outcomes are trending in the correct direction at follow-up (Aim 3).
1,473 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.
This study's planned enrollment of 20 is below the median of 63 across 1,167 interventional studies indexed under Opioid-Related Disorders.
Browse Opioid-Related Disorders studies →Lifespan is the lead sponsor of 27 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Screening Intervention
Behavioral: SHE-OUD
The SHE-OUD intervention provides screening for sexual victimization and PTSD among individuals seeking MOUD treatment with the goal of enhancing mental health treatment utilization, and enhancing OUD treatment outcomes. Aftereffects of sexual victimization are addressed (i.e., intimate partner violence, substance use) if participants endorse a risk for these concerns. All participants are provided with brief intervention for sexual victimization, PTSD, and the intersection of sexual victimization and OUD.
Mental Health Treatment Initiation
Number of participants who engage in mental health treatment for PTSD and general mental health concern, assessed by the Treatment Services Review (self-report). Treatment initiation is defined as reporting at least one service appointment in the past 30 days. This is a binary variable (yes/no), with the positive outcome being "yes" (treatment initiated).
Time frame: Measured at baseline and 1 month follow-up.
Mental Health Treatment Utilization
Number of mental health treatment sessions attended, assessed by the Treatment Services Review (self-report). Treatment utilization is defined as reporting at having two or more services. This is a binary variable (yes/no), with the positive outcome being "yes" (treatment utilized).
Time frame: Measured at baseline and 1 month follow-up.
PTSD Symptoms
Change From Baseline in The Primary Care PTSD Screen for DSM-5 scores at 1 month. Scores range from 0 to 5, with higher scores indicating greater PTSD symptoms.
Time frame: Assessed at baseline and 1-month follow-up
Intimate Partner Violence
Change From Baseline in HITS score at 1 month. Scores range from 4 to 20, with higher scores indicating greater intimate partner violence risk.
Time frame: Assessed at baseline and 1-month follow-up.
Polysubstance Use
Change From Baseline in Timeline Follow Back scores at 1 month. Frequency and type of substance use in the past 30 days will be assessed. Scores range from 0-30, with a cumulative count of substance use days or heavy drinking days.
Time frame: Assessed at baseline and 1-month follow-up.
Opioid Use
Change From Baseline in Timeline Follow Back scores at 1 month. Frequency of non-prescription opioid use in the past 30 days will be assessed. Scores range from 0-30, with a cumulative count of days engaging in opioid use.
Time frame: Assessed at baseline and 1-month follow-up.
Non-fatal overdose
Change From Baseline in Timeline Follow Back scores at 1 month. Frequency of non-fatal overdoses in the past 30 days will be assessed. Scores range from 0-30, with a cumulative count of days in which non-fatal overdoses occurred.
Time frame: Assessed at baseline and 1-month follow-up.
OUD Medication Adherence
Change From Baseline in Timeline Follow Back scores at 1 month. Self-reported data on daily buprenorphine and methadone medication adherence in the past 30 days will be assessed. Scores range from 0-30, with a cumulative count of days adhering to OUD medication.
Time frame: Assessed at baseline and 1-month follow-up.
OUD Treatment Retention
Change From Baseline in Timeline Follow Back scores at 1 month. Self-reported data on number of missed appointments and treatment dropout will be assessed. Scores range from 0-30, with a cumulative count of days in which a participant missed an appointment or dropped out of treatment.
Time frame: Assessed at baseline and 1-month follow-up.
Revictimization
Change From Baseline in 2-item Life Events Checklist at 1 month. A positive score indicates revictimization. This is a binary variable (yes/no), with the positive outcome being "yes" (revicitimization)
Time frame: Assessed at baseline and 1-month follow-up.
Trauma-related shame
Change From Baseline in Trauma-Related Shame Inventory (Short Form) scores at 1 month. Scores range from 0-30, with higher scores indicating more severe levels of trauma-related shame.
Time frame: Assessed at baseline and 1 month follow up.
Self-blame
Change From Baseline in Rape Attribution scores at 1 month. Scores range from 5 to 25, with higher scores indicating greater self blame across subscales (behavioral self-blame, characterological self-blame, blaming the rapist, blaming society, and blaming chance).
Time frame: Assessed at baseline and 1 month follow up.
Pain
Change From Baseline in PROMIS® Numeric Rating Scale v.1.0 - Pain Intensity scores at 1 month. Scores range from 0 to 10, with higher scores indicating more severe pain.
Time frame: Assessed at baseline and 1 month follow up.
Depression
Change From Baseline in Patient Health Questionnaire (PHQ-9) scores at 1 month. Scores range from 0 to 27, with higher scores indicating greater depression severity.
Time frame: Assessed at baseline and 1 month follow up.
Anxiety
Change From Baseline in Generalized Anxiety Disorder-7 (GAD-7) scores at 1 month. Scores range from 0 to 21, with higher scores indicating greater anxiety.
Time frame: Assessed at baseline and 1 month follow up.
Motivation for change
Change From Baseline in Readiness to Change (RCTQ) scores for each change target (PTSD, IPV, and polysubstance use) at 1 month. Scores range from -8 to +8 for each subscale, with higher scores indicating greater readiness to change.
Time frame: Assessed at baseline, post-intervention, and 1 month follow up.
Attitudes towards Psychological Care
Change from Attitudes Toward Seeking Professional Psychological Help Scale-Short Version (ATSPPH-SF) at 1 month. Scores range from 10 to 40, with higher scores indicating a more positive attitude toward seeking professional psychological help.
Time frame: Assessed at baseline and 1 month follow up.
Stigma
Change from Self-Stigma of Seeking Help and the Stigma Scale for Receiving Psychological Help at 1 month. Scores for the Self-Stigma of Seeking Help range from 10 to 50, with higher scores indicating a greater perceived threat to one's self-worth associated with seeking help. Scores of the Stigma Scale for Receiving Psychological Help range from 0-15, with higher scores indicating greater public stigma.
Time frame: Assessed at baseline and 1 month follow up.
Outcomes expectancies
Change from the Disclosure Expectation Scale at 1 month. Scores for Disclosure Expectations Scale range from 10 to 50; Higher scores on the positive expectations subscale indicates more positive disclosure expectations, while higher scores on the negative expectations subscale indicates more negative disclosure expectations.
Time frame: Assessed at baseline and 1 month follow up.
Intentions to seek treatment
Change from the adapted Intentions to Seek Counseling Inventory at 1 month. Scores for the Intentions to Seek Counseling Inventory range from 11-44, with higher scores reflecting a greater general willingness to seek help.
Time frame: Assessed at baseline and 1 month follow up.
Self-efficacy
Change from Self-Efficacy to Seek Mental Health Care at 1 month. Scores from the Self-Efficacy to Seek Mental Health Care range from 9-90, with higher scores reflecting greater self efficacy (perceived behavioral control).
Time frame: Assessed at baseline and 1 month follow up.
Contextual Factors
Change from Life Circumstances Scale at 1 month. Higher scores across each subscale (i.e., transportation, scheduling, cost, access) indicate greater impact on care.
Time frame: Assessed at baseline and 1 month follow up.
Intervention Satisfaction
Client Satisfaction Questionnaire (CSQ) will assess overall satisfaction with the intervention. Scores range from 8 to 32, with higher scores indicating greater satisfaction.
Time frame: Assessed immediately post-intervention as a descriptive measure (no comparison group).
Intervention Acceptability
Acceptability of Intervention (AIM) Measure will assess intervention acceptability. Scores range from 4 to 20, with higher scores indicating higher acceptability.
Time frame: Assessed immediately post-intervention as a descriptive measure (no comparison group).
Intervention Utility
The adapted Utility Questionnaire (UQ) will assess perceived intervention utility. Scores range from 0 to 56, with higher scores indicating higher utility.
Time frame: Assessed immediately post-intervention as a descriptive measure (no comparison group).
Intervention Impact
The adapted Impact Questionnaire (IQ) will assess intervention impact. Scores range from 0 to 28, with higher scores indicating higher impact.
Time frame: Assessed immediately post-intervention as a descriptive measure (no comparison group).
Intervention Usability
The CIAS satisfaction measure (Ondersma et al., 2005) will be used to assess system usability. Scores range from 7 to 35, with higher scores indicating higher usability.
Time frame: Assessed immediately post-intervention as a descriptive measure (no comparison group).
No study locations are listed for this record.
Plan to share: Yes — De-identified data and protocol information will be shared in accordance with the data sharing and management plan.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data and study information will be made available as soon as it is available at the completion of the study.
Access criteria: Data sharing agreements will be established for access to data. Data can also be accessed through the public repository.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Aug 2027, 8 months later.
Of 54 non-industry phase 1 interventional studies under Opioid-Related Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 8 months is below that.
Counting every sponsor, half of 78 studies reached it within 19 months; a quarter within 9 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lifespan